U.S. markets open in 2 hours 49 minutes
  • S&P Futures

    4,448.25
    +2.50 (+0.06%)
     
  • Dow Futures

    34,775.00
    +101.00 (+0.29%)
     
  • Nasdaq Futures

    15,274.50
    -44.25 (-0.29%)
     
  • Russell 2000 Futures

    2,252.50
    +8.50 (+0.38%)
     
  • Crude Oil

    75.04
    +1.06 (+1.43%)
     
  • Gold

    1,748.70
    -3.00 (-0.17%)
     
  • Silver

    22.56
    +0.13 (+0.58%)
     
  • EUR/USD

    1.1707
    -0.0011 (-0.09%)
     
  • 10-Yr Bond

    1.4600
    0.0000 (0.00%)
     
  • Vix

    18.35
    -0.28 (-1.50%)
     
  • GBP/USD

    1.3700
    +0.0019 (+0.14%)
     
  • USD/JPY

    110.9520
    +0.2670 (+0.24%)
     
  • BTC-USD

    43,826.86
    +824.67 (+1.92%)
     
  • CMC Crypto 200

    1,093.05
    -10.01 (-0.91%)
     
  • FTSE 100

    7,067.21
    +15.73 (+0.22%)
     
  • Nikkei 225

    30,240.06
    -8.75 (-0.03%)
     

Do Institutions Own Codiak BioSciences, Inc. (NASDAQ:CDAK) Shares?

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

A look at the shareholders of Codiak BioSciences, Inc. (NASDAQ:CDAK) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Warren Buffett said that he likes "a business with enduring competitive advantages that is run by able and owner-oriented people." So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.

Codiak BioSciences is not a large company by global standards. It has a market capitalization of US$391m, which means it wouldn't have the attention of many institutional investors. Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. Let's delve deeper into each type of owner, to discover more about Codiak BioSciences.

See our latest analysis for Codiak BioSciences

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Codiak BioSciences?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that Codiak BioSciences does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Codiak BioSciences, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. We note that hedge funds don't have a meaningful investment in Codiak BioSciences. Our data shows that Arch Venture Partners, L.P. is the largest shareholder with 17% of shares outstanding. In comparison, the second and third largest shareholders hold about 15% and 12% of the stock.

To make our study more interesting, we found that the top 5 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Codiak BioSciences

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

We can see that insiders own shares in Codiak BioSciences, Inc.. It has a market capitalization of just US$391m, and insiders have US$27m worth of shares, in their own names. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.

General Public Ownership

With a 13% ownership, the general public have some degree of sway over Codiak BioSciences. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

With a stake of 29%, private equity firms could influence the Codiak BioSciences board. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Codiak BioSciences (at least 1 which doesn't sit too well with us) , and understanding them should be part of your investment process.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.